These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9044174)

  • 1. The high price of schizophrenia. Georgia restricts newer anti-psychotics for Medicaid members.
    J Psychosoc Nurs Ment Health Serv; 1997 Feb; 35(2):6-7. PubMed ID: 9044174
    [No Abstract]   [Full Text] [Related]  

  • 2. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
    Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
    Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of schizophrenia: let's talk dollars and sense.
    Buckley PF
    Am J Manag Care; 1998 Mar; 4(3):369-83. PubMed ID: 10178499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia-related outpatient treatment of Medicaid-financed patients after hospital discharge.
    van den Noort M; Bosch P
    J Clin Psychiatry; 2011 Jan; 72(1):113; author reply 113-4. PubMed ID: 21272517
    [No Abstract]   [Full Text] [Related]  

  • 7. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
    Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
    Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of conventional antipsychotics and the cost of treating schizophrenia.
    Lyu RR; McCombs JS; Johnstone BM; Muse DN
    Health Care Financ Rev; 2001; 23(2):83-99. PubMed ID: 12500340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to atypical antipsychotics: a public payor's perspective.
    Haveman JK
    Behav Healthc Tomorrow; 1998 Aug; 7(4):45-8. PubMed ID: 10182153
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a managed behavioral health carve-out on quality of care for medicaid patients diagnosed as having schizophrenia.
    Busch AB; Frank RG; Lehman AF
    Arch Gen Psychiatry; 2004 May; 61(5):442-8. PubMed ID: 15123488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D
    J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing effectiveness research and improving care for schizophrenia in real-world settings.
    Buckley PF; Miller A; Chiles JA; Sajatovic M
    Am J Manag Care; 1999 Jun; 5 Spec No():SP47-56. PubMed ID: 10538860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left behind: the seriously mentally ill in the managed care era. Interview by Robin Dorman.
    Torrey EF; Fisher D
    Behav Healthc Tomorrow; 1998 Dec; 7(6):12-4, 31-3. PubMed ID: 10187561
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

  • 19. Atypical antipsychotics in the managed care era.
    Loebel AD; Botts SR; Feldman BI
    Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of schizophrenia in the 21st century.
    Hanson MA
    J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.